How much does a box of Enxidiping cost in 2024?

Enasidenib is a targeted anti-cancer drug used to treat certain types of acute myeloid leukemia (AML), particularly those with mutations in isocitrate dehydrogenase 2 (IDH2). AML is a cancer that affects the white blood cells in the bone marrow, causing bone marrow dysfunction and the proliferation of abnormal white blood cells. IDH2mutations are common in some AML patients. Such mutations can lead to abnormal metabolic pathways and promote the growth and survival of cancer cells. Ensidipine restores the normal metabolic process of cells by inhibiting the mutated IDH2 enzyme, inducing the differentiation and apoptosis of cancer cells, thereby inhibiting cancer progression.

The efficacy of ensidipine has been demonstrated in multiple clinical trials. Studies have shown that patients with IDH2-mutated AML who received ensidipine showed significant response rates, prolonged progression-free survival and improved overall survival. These results significantly improved patient outcomes. Ensidipine is usually given as an oral tablet once daily. Common side effects include nausea, vomiting, diarrhea, fatigue and loss of appetite. In addition, ensidipine may cause a serious complication called differentiation syndrome, an inflammatory response caused by rapid differentiation of cancer cells that requires prompt recognition and treatment.

Currently, ensidipine is not yet available in mainland China, so domestic patients cannot purchase this drug directly. To obtain ensidipine, patients need to purchase it through overseas channels. There are some cheaper generic drugs on the foreign market, mainly from Laos and Bangladesh. The price of these generic drugs is about 2,000 yuan, and their pharmaceutical ingredients are basically the same as the original drugs, with similar efficacy and safety. The emergence of generic drugs has provided many patients with affordable treatment options.

As a targeted therapy, ensidipine has greatly changed the treatment paradigm for specific AML patients, providing an effective treatment option for those carrying IDH2 mutations. Although its scope is limited, ensidipine can provide significant therapeutic benefit to patients when the presence of the mutation is confirmed through genetic testing. Overall, the development and application of ensidipine marks an important progress in the treatment field of AML, bringing more hope for survival and treatment options to patients through precision treatment.